KFDA to exclude new drugs in re-examination from list of items subject to notification

The Korea Food and Drug Administration announced on August 11 that new drugs in the process of re-examination will be excluded from the list of notification items whose safety and efficacy has been already established, as part of efforts to facilitate the product application procedures of drug makers or importers.

Items to be excluded from the notification include new drugs, gene recombinant...